Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Merck
Biotech
Merck's HIV combo treatment meets efficacy bar in phase 3 trials
Two phase 3 studies assessing a combo of Merck's approved doravirine and investigational islatravir met their primary efficacy goals.
Zoey Becker
Dec 19, 2024 11:54am
Amgen, Merck join academic clinical trial diversity partnership
Sep 16, 2024 3:10pm
ESMO: Cancer vaccine and Keytruda deliver in phase 2 trial
Sep 14, 2024 2:30am
Merck to use N-Power clinical trial platform for cancer studies
Jul 1, 2024 4:20pm
Merck compares pneumococcal vaccine to 1983 warhorse
Apr 29, 2024 9:00am
Merck inks R&D deal with Intermountain spinoff Culmination Bio
Jan 25, 2024 9:30am
